Mirae Asset Global Investments Co. Ltd. Has $250.10 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.7% in the third quarter, Holdings Channel.com reports. The firm owned 284,907 shares of the company’s stock after buying an additional 27,580 shares during the quarter. Eli Lilly and Company comprises approximately 1.1% of Mirae Asset Global Investments Co. Ltd.’s investment portfolio, making the stock its 14th biggest position. Mirae Asset Global Investments Co. Ltd.’s holdings in Eli Lilly and Company were worth $250,098,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. M&G Plc acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. Virtu Financial LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $2,138,000. China Universal Asset Management Co. Ltd. grew its holdings in Eli Lilly and Company by 19.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after acquiring an additional 1,620 shares during the last quarter. Mutual Advisors LLC grew its holdings in Eli Lilly and Company by 404.8% during the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after acquiring an additional 50,197 shares during the last quarter. Finally, Private Advisor Group LLC grew its holdings in Eli Lilly and Company by 0.6% during the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after acquiring an additional 430 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.2 %

Shares of NYSE LLY opened at $892.70 on Friday. The firm has a market cap of $848.45 billion, a PE ratio of 109.94, a P/E/G ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company’s fifty day simple moving average is $919.74 and its 200 day simple moving average is $862.48. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, sell-side analysts forecast that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.